For over 50 years, Ziehm Imaging has been at the forefront of developing advanced technologies that enhance medical imaging and optimize clinical workflows. Our mobile C-arm solutions deliver outstanding image quality, reduced X-ray dose, and user-friendly operation. By continuously setting new standards in X-ray-based imaging, we drive innovation that improves patient care and transforms lives around the world. | For over 50 years, Ziehm Imaging technologies enhance imaging and streamline clinical workflows. Our technology provides innovative solutions for improved image quality, minimized X-ray dose and unparalleled ease-of-use. By setting new technological standards in X-ray-based imaging solutions with our mobile C-arms, we are leading innovations and changing lives all over the world.
VERO Biotech Inc.
VERO Biotech Inc, headquartered in Atlanta, Georgia, is a trailblazer in the life sciences sector, focusing on enhancing patient outcomes, in the acute care setting, through cutting-edge technologies. Our flagship product, the GENOSYL® Delivery System (DS), epitomizes our commitment to innovation. Designed with precision, it stands as the market’s premier tankless inhaled nitric oxide (iNO) delivery system, celebrated for its safety, efficacy, and ease of use. Adopted by a third of hospitals utilizing nitric oxide therapy, including leading medical institutions, GENOSYL DS has positively impacted neonatal and acute care settings.
Synapse Biomedical
Synapse Biomedical Inc., markets the NeuRx Diaphragm Pacing System® a surgically implanted neurostimulator. The system is FDA approved for treating ventilator dependency from high spinal cord injury and chronic hypoventilation from ALS (Lou Gehrig’s disease).
Prenosis
Prenosis is a biology-based technology company redefining the standard of care for critical conditions. We believe healthcare should not follow a one-size-fits-all model. Instead, our mission is to tailor healthcare to each patient’s biology through the creation and delivery of integrated diagnostics and therapeutics. We use deep data and AI to build tools that augment clinical diagnosis of critical conditions based on each patient’s unique biological profile. Unlike other AI-driven diagnostics, we go further by developing therapies that help providers deliver personalized care. Our Immunix™ platform powers the development of a variety of AI-based diagnostics, including Sepsis ImmunoScore®, the first FDA-authorized AI diagnostic tool for sepsis. At Prenosis, we see people differently. For more information, visit us at prenosis.com or find us on LinkedIn.